Literature DB >> 16669962

Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.

N T Gunaratnam1, T P Jessup, J Inadomi, D P Lascewski.   

Abstract

BACKGROUND: Proton pump inhibitors are the most potent drug treatment for gastro-oesophageal reflux disease. Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy. AIM: To determine the prevalence of sub-optimal proton pump inhibitor dosing in a community-based gastro-oesophageal reflux disease population.
MATERIALS AND METHODS: One hundred patients on proton pump inhibitors referred for persistent gastro-oesophageal reflux disease symptoms were questioned about their proton pump inhibitor dosing habits and classified as optimal or sub-optimal dosers. Optimal dosers took proton pump inhibitors with or up to 60 min before meals. Sub-optimal dosers took proton pump inhibitors >60 min before meals, after meals, as needed, or at bedtime.
RESULTS: Forty-six percent dosed optimally. Fifty-four percent dosed sub-optimally with 21 of 54 (39%) dosing >60 min before meals, 16 (30%) after meals, 15 (28%) at bedtime and two (4%) as needed. Only 6% of the subjects on once-daily proton pump inhibitor regimens and 33% of subjects taking proton pump inhibitors two- to three times daily dosed in a manner that maximized acid suppression (15-30 min before a meal).
CONCLUSIONS: In this study, 54% of patients dosed proton pump inhibitors sub-optimally and only 12% dosed in a manner that maximized acid suppression. As sub-optimal proton pump inhibitor dose timing can limit efficacy, patients with refractory symptoms should be asked about dose timing to avoid inappropriate and costly dose escalations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16669962     DOI: 10.1111/j.1365-2036.2006.02911.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  28 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

3.  Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.

Authors:  Yoshikazu Kinoshita; Shunji Ishihara
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

Review 4.  Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?

Authors:  Andrew J Gawron; John E Pandolfino
Journal:  Curr Gastroenterol Rep       Date:  2013-04

5.  Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease.

Authors:  Benjamin D Rogers; C Prakash Gyawali
Journal:  Indian J Gastroenterol       Date:  2019-10

Review 6.  Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Kelli DeLay
Journal:  Med Clin North Am       Date:  2018-11-01       Impact factor: 5.456

Review 7.  Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease.

Authors:  Michele Cicala; Sara Emerenziani; Michele Pier Luca Guarino; Mentore Ribolsi
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

8.  New Approaches to Management of PPI-Refractory Gastroesophageal Reflux Disease.

Authors:  Fehmi Ates; Michael F Vaezi
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 9.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

Review 10.  Refractory GERD: what is it?

Authors:  Ronnie Fass; Anita Gasiorowska
Journal:  Curr Gastroenterol Rep       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.